Literature DB >> 8829111

Calciphylaxis in chronic renal failure.

M N Budisavljevic1, D Cheek, D W Ploth.   

Abstract

Calciphylaxis is a rare and life-threatening complication that is estimated to occur in 1% of patients with ESRD each year. Typically, extensive microvascular calcification and occlusion/thrombosis leads to violaceous skin lesions, which progress to nonhealing ulcers and sepsis. Secondary infection of skin lesions is common, often leading to sepsis and death. The lower extremities are predominantly involved (roughly 90% of patients). Patients with skin involvement over the trunk or proximal extremities have a poorer prognosis. Although most calciphylaxis patients have abnormalities of the calcium:phosphate axis or elevated levels of parathyroid hormone, these abnormalities do not appear to be fundamental to the pathophysiology of the disorder, and the etiology of calciphylaxis remains unclear. Recently, functional protein C deficiency has been hypothesized to cause a hypercoagulable state that could induce thrombosis in small vessels, with resulting skin ischemia, necrosis, and gangrene. The lack of understanding of the pathophysiology of the disease results in treatments that are equally unsatisfactory. Patients who undergo parathyroidectomy have a tendency to improve, but the prognosis for the disease is poor and mortality remains high.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8829111     DOI: 10.1681/ASN.V77978

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  40 in total

Review 1.  Calciphylaxis and vascular calcification: a continuum of extra-skeletal osteogenesis.

Authors:  Sharon M Moe; Neal X Chen
Journal:  Pediatr Nephrol       Date:  2003-10       Impact factor: 3.714

2.  Calciphylaxis.

Authors:  J E M Young
Journal:  CMAJ       Date:  2012-02-21       Impact factor: 8.262

3.  Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis.

Authors:  Joan Perelló; Miquel D Ferrer; Maria Del Mar Pérez; Nadine Kaesler; Vincent M Brandenburg; Geert J Behets; Patrick C D'Haese; Rekha Garg; Bernat Isern; Alex Gold; Myles Wolf; Carolina Salcedo
Journal:  Br J Pharmacol       Date:  2020-08-23       Impact factor: 8.739

Review 4.  Calciphylaxis: from the disease to the diseased.

Authors:  Tiago M Oliveira; João M Frazão
Journal:  J Nephrol       Date:  2015-04-03       Impact factor: 3.902

5.  Calciphylaxis: evolving concepts.

Authors:  Giovanni Garini; Elisa Galletti; Roberto Ricci; Augusto Vaglio; Carlo Buzio
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

Review 6.  [Calciphylaxis. A call for interdisciplinary cooperation].

Authors:  V M Brandenburg; S Schmitz; J Floege; K Amann; M Ketteler
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

7.  Painful skin ulcers in a hemodialysis patient.

Authors:  Stuart M Sprague
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-07       Impact factor: 8.237

8.  Quantifying a rare disease in administrative data: the example of calciphylaxis.

Authors:  Sagar U Nigwekar; Craig A Solid; Elizabeth Ankers; Rajeev Malhotra; William Eggert; Alexander Turchin; Ravi I Thadhani; Charles A Herzog
Journal:  J Gen Intern Med       Date:  2014-08       Impact factor: 5.128

9.  Sodium thiosulfate therapy for calcific uremic arteriolopathy.

Authors:  Sagar U Nigwekar; Steven M Brunelli; Debra Meade; Weiling Wang; Jeffrey Hymes; Eduardo Lacson
Journal:  Clin J Am Soc Nephrol       Date:  2013-03-21       Impact factor: 8.237

10.  Surviving calciphylaxis.

Authors:  Paul Lee; Jacob Sevastos; Lesley V Campbell
Journal:  J Bone Miner Metab       Date:  2008-12-05       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.